Cargando…
Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484350/ https://www.ncbi.nlm.nih.gov/pubmed/26118971 http://dx.doi.org/10.1038/srep11720 |
_version_ | 1782378647095607296 |
---|---|
author | Jiao, Yi-Sheng Gong, Ting-Ting Wang, Yong-Lai Wu, Qi-Jun |
author_facet | Jiao, Yi-Sheng Gong, Ting-Ting Wang, Yong-Lai Wu, Qi-Jun |
author_sort | Jiao, Yi-Sheng |
collection | PubMed |
description | The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presence versus absence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I(2) = 31.2%, P = 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I(2) = 0%, P = 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients. |
format | Online Article Text |
id | pubmed-4484350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44843502015-07-08 Comorbidity and survival among women with ovarian cancer: evidence from prospective studies Jiao, Yi-Sheng Gong, Ting-Ting Wang, Yong-Lai Wu, Qi-Jun Sci Rep Article The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presence versus absence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I(2) = 31.2%, P = 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I(2) = 0%, P = 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients. Nature Publishing Group 2015-06-29 /pmc/articles/PMC4484350/ /pubmed/26118971 http://dx.doi.org/10.1038/srep11720 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Jiao, Yi-Sheng Gong, Ting-Ting Wang, Yong-Lai Wu, Qi-Jun Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title | Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title_full | Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title_fullStr | Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title_full_unstemmed | Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title_short | Comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
title_sort | comorbidity and survival among women with ovarian cancer: evidence from prospective studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484350/ https://www.ncbi.nlm.nih.gov/pubmed/26118971 http://dx.doi.org/10.1038/srep11720 |
work_keys_str_mv | AT jiaoyisheng comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies AT gongtingting comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies AT wangyonglai comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies AT wuqijun comorbidityandsurvivalamongwomenwithovariancancerevidencefromprospectivestudies |